openPR Logo
Press release

Idiopathic Pulmonary Fibrosis Disease (Respiratory) pipeline Forecast Report, H1, 2017 – Pharmaceutical Latest Pipeline Guide

05-31-2017 04:01 PM CET | Health & Medicine

Press release from: Market Research Provider - MRH

Market Research Hub

Market Research Hub

Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1070447

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 13, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Market Research Hubs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Browse Full Report with TOC @ http://www.marketresearchhub.com/report/idiopathic-pulmonary-fibrosis-pipeline-review-h1-2017-report.html

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents:
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 9
Market Research Hub Report Coverage 9
Idiopathic Pulmonary Fibrosis - Overview 10
Idiopathic Pulmonary Fibrosis - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 18
Products under Development by Companies 19
Products under Development by Universities/Institutes 24
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment 25
Assessment by Target 25
Assessment by Mechanism of Action 29
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development 37
AdAlta Ltd 37
Aeolus Pharmaceuticals Inc 37
Allinky Biopharma 38
apceth Biopharma GmbH 38
Apellis Pharmaceuticals Inc 39
Asahi Kasei Pharma Corp 39
aTyr Pharma Inc 40
Biogen Inc 40

About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Follow Us on:
Twitter: https://twitter.com/MktResearchHub/
LinkedIn: https://www.linkedin.com/company/market-research-hub/
Facebook: https://www.facebook.com/MarketResearchHub/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Idiopathic Pulmonary Fibrosis Disease (Respiratory) pipeline Forecast Report, H1, 2017 – Pharmaceutical Latest Pipeline Guide here

News-ID: 558332 • Views:

More Releases from Market Research Provider - MRH

Global Sports Accessories Market Status & Growth Analysis Forecasted till 2022
Global Sports Accessories Market Status & Growth Analysis Forecasted till 2022
Market Research Hub (MRH) has included a new report titled “Global Sports Accessories Market Research Report 2017”, to its huge database. This research study includes information about the regional production along with revenue and market share. The report further updates that the sports market on the global level would acquire a rise at a positive CAGR during the period 2017-2022, which is surely a major boost for the concerned sector.
Global Film Release Liners Market to Rise at an Impressive Rate during the Forecast Period of 2017 – 2022
Global Film Release Liners Market to Rise at an Impressive Rate during the Forec …
The demand for film release liners is greatly influenced by the advancements in the packaging industry. The increased preference for modern and latest packaging all across the world, coupled with the increasing investments in the pharmaceuticals and the food and beverages industries, is expected to drive the demand in the global market for film release liners over the coming years. A new market report with a title “Global Film Release
Global Coated Graphite Market Status, Trends & Future Outlook until 2022
Global Coated Graphite Market Status, Trends & Future Outlook until 2022
The latest research report added to the vast database of Market Research Hub (MRH). The study is titled “Global Coated Graphite Market Research Report 2017”, which includes information about the regional segmentation on the basis of factors such as production, consumption, revenue, and market share. It is also mentioned that the market would soon acquire growth at a double-digit CAGR between 2017 and 2022. Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1217172 Geographically, this

More Releases for Pulmonary

Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027. Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion. Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Pulmonary Embolism - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Pulmonary Embolism - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2017, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape. Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in
03-15-2017 | Health & Medicine
TMR
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments